Adverse Events of Nivolumab in Patients With Advanced, Non-Squamous NSCLC
Mark A. Socinski, MD, professor, Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, University of Pittsburgh, discusses the adverse events, as well as the overall significance, of nivolumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Socinski, mentions a few adverse events, such as fatigue, skin rash, and diarrhea, but then explains that most of these are grades 1 and 2. Very few are grades 3 and 4, but Socinski urges oncologists to be aware of the different toxicities and know how to treat them.
Socinski believes this trial is significant because it presents another monotherapy, other than docetaxel, and it happens to be better in terms of overall survival.
Mark A. Socinski, MD, professor, Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, University of Pittsburgh, discusses the adverse events, as well as the overall significance, of nivolumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
February 17th 2025During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON trials of immunotherapy in patients with metastatic non–small cell lung cancer.
Read More
